Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats.
Pre-treatment of male Sprague-Dawley rats with long-acting bromocryptine microcapsules (CBLA) significantly inhibited the arthritic response to Freund's complete adjuvant and reduced weight loss, thymolysis, splenomegaly and leukocytosis. In the prevention of adjuvant arthritis (AA), the combination of CBLA plus sub-optimal doses of cyclosporine A (CsA) was more efficient than either of the drugs alone. Sub-optimal doses of CsA were 0.1 and 1.0 mg/kg/day s.c. for 5 days. Furthermore, CBLA alone did not decrease the incidence of experimental allergic uveitis (EAU) in the male Lewis rats. Low-dose CsA reduced the incidence of uveitis by 50%, and with the addition of CBLA, 100% of rats were protected. Low-dose CsA was 2 mg/kg/day i.m. for 14 days. Long-term treatment of male Sprague-Dawley rats with CBLA alone reduced the incidence and severity of spontaneous autoimmune periarteritis nodosa (PN) in a dose-dependent manner; CsA was less potent than CBLA, and only additive effects were obtained. Finally, for the prevention of spontaneous autoimmune insulin-dependent diabetes (DM), the administration of CBLA did not improve the effect of a low-dose CsA in male BB rats. Nevertheless, a delay in onset of DM could be achieved. A sequential therapy using CsA plus CBLA clearly showed beneficial effects. The dose of CsA was 10 mg/kg p.o. 6 days/week for 21 weeks. Compared with Sprague-Dawley or Lewis male rats, BB male rats showed only weak prolactin suppression after the same doses of CBLA. It is suggested that the use of CBLA may be particularly beneficial in autoimmune disorders. The effectiveness of the combination therapy CBLA plus CsA, however, was dependent on the model considered. Various factors could play a role: (1) the different ways of administering CsA (s.c. in AA, i.m. in EAU and PN, oral in DM); (2) strain-dependency in the capacity of CBLA to suppress Prl secretion; and (3) at least in the BB rats, the transient increase of CsA bioavailibility which was possibly induced by CBLA.
Neidhart
M
M
Department of Rheumatology, University Hospital Zurich, Switzerland.
D000818:Animals; D001169:Arthritis, Experimental / Q000517:prevention & control; D001327:Autoimmune Diseases / Q000517:prevention & control*; D001971:Bromocriptine / Q000008:administration & dosage*; D016572:Cyclosporine / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control; D004357:Drug Synergism; D005260:Female; D008297:Male; D009955:Ornithine Decarboxylase / Q000378:metabolism; D010488:Polyarteritis Nodosa / Q000517:prevention & control; D051381:Rats; D011913:Rats, Inbred BB; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D013950:Thymus Gland / Q000201:enzymology; D014605:Uveitis / Q000517:prevention & control
D003692:Delayed-Action Preparations; D001971:Bromocriptine; D016572:Cyclosporine; D009955:Ornithine Decarboxylase